HUP0301784A2 - Imidazol és benzimidazol bifenilszármazékai, alkalmazásuk, eljárás a vegyületek előállítására és ezeket tartalmazó gyógyszerkészítmények - Google Patents
Imidazol és benzimidazol bifenilszármazékai, alkalmazásuk, eljárás a vegyületek előállítására és ezeket tartalmazó gyógyszerkészítményekInfo
- Publication number
- HUP0301784A2 HUP0301784A2 HU0301784A HUP0301784A HUP0301784A2 HU P0301784 A2 HUP0301784 A2 HU P0301784A2 HU 0301784 A HU0301784 A HU 0301784A HU P0301784 A HUP0301784 A HU P0301784A HU P0301784 A2 HUP0301784 A2 HU P0301784A2
- Authority
- HU
- Hungary
- Prior art keywords
- compounds
- hal
- mono
- independently
- benzimidazole
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 title 3
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 title 1
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical class C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- JYEUMXHLPRZUAT-UHFFFAOYSA-N 1,2,3-triazine Chemical compound C1=CN=NN=C1 JYEUMXHLPRZUAT-UHFFFAOYSA-N 0.000 abstract 1
- 206010003210 Arteriosclerosis Diseases 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000001132 Osteoporosis Diseases 0.000 abstract 1
- 208000037273 Pathologic Processes Diseases 0.000 abstract 1
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 abstract 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 abstract 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 abstract 1
- DPOPAJRDYZGTIR-UHFFFAOYSA-N Tetrazine Chemical group C1=CN=NN=N1 DPOPAJRDYZGTIR-UHFFFAOYSA-N 0.000 abstract 1
- 208000007536 Thrombosis Diseases 0.000 abstract 1
- 230000033115 angiogenesis Effects 0.000 abstract 1
- 238000002399 angioplasty Methods 0.000 abstract 1
- 125000006615 aromatic heterocyclic group Chemical group 0.000 abstract 1
- 208000011775 arteriosclerosis disease Diseases 0.000 abstract 1
- 125000002619 bicyclic group Chemical group 0.000 abstract 1
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 abstract 1
- 208000029078 coronary artery disease Diseases 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 102000006495 integrins Human genes 0.000 abstract 1
- 108010044426 integrins Proteins 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 125000002950 monocyclic group Chemical group 0.000 abstract 1
- 208000010125 myocardial infarction Diseases 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 230000009054 pathological process Effects 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 230000000644 propagated effect Effects 0.000 abstract 1
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 abstract 1
- 208000037803 restenosis Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/30—Nitrogen atoms not forming part of a nitro radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/44—Nitrogen atoms not forming part of a nitro radical
- C07D233/48—Nitrogen atoms not forming part of a nitro radical with acyclic hydrocarbon or substituted acyclic hydrocarbon radicals, attached to said nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/88—Nitrogen atoms, e.g. allantoin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Surgery (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Vascular Medicine (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
A találmány (I) általános képletű vegyületekre - a képletben R1jelentése OR vagy N(R)2, R2 és R3 jelentése minden egyes esetben,egymástól függetlenül H, A, Hal, NO2, OR, N(R)2, CN, CO-R, SO3R, SO2R,NH-C(O)A vagy SR, R4 jelentése mono- vagy biciklusos aromásheterociklusos csoport, amely 1-4 nitrogénatomot tartalmaz, és amelyHal, R, OR, CN, N(R5)2 vagy NO2 csoporttal lehet mono- vagydiszubsztituálva, a piridin-, piridazin-, pirimidin-, pirazin-,1,3,5-, 1,2,4- és 1,2,3-triazin- és tetrazingyűrű kivételével, R5jelentése H vagy A, n és m értéke egymástól függetlenül 1, 2, 3, 4, 5vagy 6, o értéke 1, 2, 3 vagy 4, p értéke l , 2, 3, 4 vagy 5 - ésfiziológiásan elfogadható sóikra és szolvátjaikra vonatkozik. Atalálmány szerinti vegyületek integrin inhibitor aktivitássalrendelkeznek, és trombózisok, szívinfarktus, szívkoszorúér betegségek,arterioszklerózis, gyulladások, tumorok, csontritkulás, fertőzések ésangioplasztikát követő resztenózis vagy angiogenezis által támogatottvagy terjesztett patológiás folyamatok leküzdésére alkalmazhatók. Atalálmány kiterjed a vegyületek előállítási eljárására és ezekettartalmazó gyógyszerkészítményekre is. Ó
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10041423A DE10041423A1 (de) | 2000-08-23 | 2000-08-23 | Biphenylderivate |
| PCT/EP2001/008970 WO2002016328A1 (de) | 2000-08-23 | 2001-08-02 | Biphenylderivate und ihre verwendung als integrininhibitoren |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HUP0301784A2 true HUP0301784A2 (hu) | 2003-12-29 |
| HUP0301784A3 HUP0301784A3 (en) | 2004-03-29 |
Family
ID=7653540
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU0301784A HUP0301784A3 (en) | 2000-08-23 | 2001-08-02 | Biphenyl derivatives, of imidazole and benzimidazole the use thereof, process for the preparation of compounds and pharmaceutical compositions containing them |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20040010023A1 (hu) |
| EP (1) | EP1311489A1 (hu) |
| JP (1) | JP2004524264A (hu) |
| KR (1) | KR20030022418A (hu) |
| CN (1) | CN1447799A (hu) |
| AU (1) | AU2001277561A1 (hu) |
| BR (1) | BR0113374A (hu) |
| CA (1) | CA2420208A1 (hu) |
| CZ (1) | CZ2003671A3 (hu) |
| DE (1) | DE10041423A1 (hu) |
| HU (1) | HUP0301784A3 (hu) |
| MX (1) | MXPA03001557A (hu) |
| NO (1) | NO20030813D0 (hu) |
| PL (1) | PL359668A1 (hu) |
| SK (1) | SK2962003A3 (hu) |
| WO (1) | WO2002016328A1 (hu) |
| ZA (1) | ZA200302256B (hu) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10112771A1 (de) | 2001-03-16 | 2002-09-26 | Merck Patent Gmbh | Inhibitoren des Integrins alpha¶v¶beta¶6¶ |
| DE10127041A1 (de) * | 2001-06-02 | 2002-12-05 | Merck Patent Gmbh | Integrinantagonisten |
| AU2005229015C1 (en) * | 2004-04-02 | 2013-01-17 | The Regents Of The University Of California | Methods and compositions for treating and preventing disease associated with alphaVbeta5 integrin |
| EP2456460A4 (en) | 2009-07-24 | 2013-02-20 | Univ California | METHODS AND COMPOSITIONS FOR TREATING AND PREVENTING INEGRINE V ASSOCIATED DISEASES |
| US11046685B2 (en) | 2017-02-28 | 2021-06-29 | Morphic Therapeutic, Inc. | Inhibitors of (α-v)(β-6) integrin |
| EP3589627A4 (en) | 2017-02-28 | 2020-08-05 | Morphic Therapeutic, Inc. | INHIBITORS OF (ALPHA-V) (BETA-6) -INTEGRIN |
| CN112312910A (zh) | 2018-04-12 | 2021-02-02 | 莫菲克医疗股份有限公司 | 人整合素α4β7拮抗剂 |
| MX2021002181A (es) | 2018-08-29 | 2021-07-15 | Morphic Therapeutic Inc | Inhibicion de la integrina alfa v beta 6. |
| US11104661B1 (en) | 2019-10-16 | 2021-08-31 | Morphic Therapeutic, Inc. | Inhibiting human integrin (α-4) (β-7) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU713676B2 (en) * | 1996-01-16 | 1999-12-09 | Merck & Co., Inc. | Integrin receptor antagonists |
| JP2001524465A (ja) * | 1997-11-24 | 2001-12-04 | メルク エンド カムパニー インコーポレーテッド | 細胞接着阻害剤としての置換β−アラニン誘導体 |
| EP1153014B1 (de) * | 1999-02-20 | 2004-09-22 | MERCK PATENT GmbH | Beta-alaninderivate |
-
2000
- 2000-08-23 DE DE10041423A patent/DE10041423A1/de not_active Withdrawn
-
2001
- 2001-08-02 MX MXPA03001557A patent/MXPA03001557A/es unknown
- 2001-08-02 CA CA002420208A patent/CA2420208A1/en not_active Abandoned
- 2001-08-02 SK SK296-2003A patent/SK2962003A3/sk unknown
- 2001-08-02 CZ CZ2003671A patent/CZ2003671A3/cs unknown
- 2001-08-02 AU AU2001277561A patent/AU2001277561A1/en not_active Abandoned
- 2001-08-02 US US10/362,234 patent/US20040010023A1/en not_active Abandoned
- 2001-08-02 PL PL01359668A patent/PL359668A1/xx unknown
- 2001-08-02 EP EP01955384A patent/EP1311489A1/de not_active Withdrawn
- 2001-08-02 KR KR10-2003-7002577A patent/KR20030022418A/ko not_active Application Discontinuation
- 2001-08-02 CN CN01814416A patent/CN1447799A/zh active Pending
- 2001-08-02 HU HU0301784A patent/HUP0301784A3/hu unknown
- 2001-08-02 JP JP2002521429A patent/JP2004524264A/ja active Pending
- 2001-08-02 WO PCT/EP2001/008970 patent/WO2002016328A1/de not_active Application Discontinuation
- 2001-08-02 BR BR0113374-8A patent/BR0113374A/pt not_active Application Discontinuation
-
2003
- 2003-02-21 NO NO20030813A patent/NO20030813D0/no unknown
- 2003-03-20 ZA ZA200302256A patent/ZA200302256B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2002016328A1 (de) | 2002-02-28 |
| NO20030813L (no) | 2003-02-21 |
| PL359668A1 (en) | 2004-08-23 |
| KR20030022418A (ko) | 2003-03-15 |
| JP2004524264A (ja) | 2004-08-12 |
| SK2962003A3 (en) | 2003-06-03 |
| HUP0301784A3 (en) | 2004-03-29 |
| CA2420208A1 (en) | 2003-02-21 |
| CN1447799A (zh) | 2003-10-08 |
| MXPA03001557A (es) | 2003-06-06 |
| CZ2003671A3 (cs) | 2003-06-18 |
| EP1311489A1 (de) | 2003-05-21 |
| AU2001277561A1 (en) | 2002-03-04 |
| NO20030813D0 (no) | 2003-02-21 |
| BR0113374A (pt) | 2003-07-08 |
| US20040010023A1 (en) | 2004-01-15 |
| ZA200302256B (en) | 2004-07-26 |
| DE10041423A1 (de) | 2002-03-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE296826T1 (de) | Pyrazolo(1,5)pyridinderivate | |
| CA2277949A1 (en) | Disubstituted bicyclic heterocycles, the preparation and the use thereof as pharmaceutical compositions | |
| DE69310367T2 (de) | Anilide-derivate | |
| NO20035583D0 (no) | Imidazo` 1,2-A pyridinderivater for profylakse og behandling av herpes virale infeksjoner | |
| HUP0401339A2 (hu) | Új 4-anilino-3-kinolinkarboxamidok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények | |
| HUP0400641A2 (hu) | Pirazolvegyületek mint proteinkináz inhibitorok és ezeket tartalmazó gyógyszerkészítmények | |
| ATE376547T1 (de) | Derivate des indol-typs als p38 kinase inhibitoren | |
| SE9904505D0 (sv) | Novel compounds | |
| RU95108387A (ru) | Дикетопиперазин, способ его получения, фармацевтическая композиция, применение дикетопиперазина | |
| MY136430A (en) | N-adamantylmethyl derivatives, pharmaceutical compositions containing them and processes for their preparation | |
| NO951166L (no) | 3-,8-substituerte deuteroporfyrinderivater, farmasöytiske preparater som inneholder dem, og fremgangsmåter for fremstilling av dem | |
| CA2337825A1 (en) | Disubstituted bicyclic heterocycles, the preparation thereof and their use as pharmaceutical compositions | |
| HUP0301784A2 (hu) | Imidazol és benzimidazol bifenilszármazékai, alkalmazásuk, eljárás a vegyületek előállítására és ezeket tartalmazó gyógyszerkészítmények | |
| HUP0401080A2 (hu) | Új görcsoldó sószármazékok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények | |
| TR199801840A2 (xx) | Yeni imidazolidin t�revleri ve bunlar� i�eren farmakolojik preparatlar. | |
| GEP20053617B (en) | Bridged Piperazine Derivatives | |
| HUP0104033A2 (hu) | Benzoilpiridazin-származékok, a vegyületeket tartalmazó gyógyszerkészítmények, eljárás az előállításukra és alkalmazásuk | |
| CA2348391A1 (en) | Chromenone and chromanone derivatives as integrin inhibitors | |
| WO2000048996A3 (de) | Beta-alaninderivate | |
| HUP0101482A2 (hu) | Piperidinil- és N-amidino-piperidinil-származékok, alkalmazásuk gyógyszerkészítmények előállítására és ezeket a vegyületeket tartalmazó gyógyszerkészítmények | |
| GB0223232D0 (en) | Chemical compounds | |
| ATE219085T1 (de) | 2-beta-substituierte-6-alkylidenpenizillansäure derivate als beta-laktamase inhibitoren | |
| MXPA03005431A (es) | Derivados de urea y uretano como inhibidores de integrina. | |
| MXPA02004441A (es) | Derivados de isoxazol como inhibidores de la fosfodiesterasa. | |
| HUP9904638A2 (hu) | Szubsztituált benzopiránszármazékok alkalmazása gyógyszerkészítmények előállítására |